Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Insider Monkey on MSN9d
Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently
We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...
This weight-loss drug stock could deliver a 90% return in 2025
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Metsera started by Guggenheim at buy on obesity drug opportunity
Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...
Insider Monkey9d
Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently
In this article, we are going to take a look at where Metsera (NASDAQ:MTSR) stands against other stocks insiders spent the most money on recently. As the broader market continues to rise this year ...
Metsera initiated with an Outperform at Evercore ISI
Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...
Metsera to Present at TD Cowen’s 45th Annual Health Care Conference
A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...
Why this newly public biotech could become a force in obesity treatments
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...
Nasdaq25d
Insider Purchase: Director at $MTSR Buys 1,432,224 Shares
Kristina Burow, a director at $MTSR, bought 1,432,224 shares of the company on 02-03-2025 for an estimated $25,780,032. This trade was reported by Quiver Quantitative ...